Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
References:
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 30, No. 4, 2016.
















